Pan Tumor Rollover Study on Long-Term Safety of Nivolumab and Other Cancer Treatments

Sponsor: Bristol-Myers Squibb

Sponsor score: 60
Inactive

ClinicalTrials ID:NCT03899155

Provider View

This study is focused on understanding the long-term safety of using nivolumab, alone or in combination with other cancer treatments, across different types of tumors.

Patient Parameters

Program Overview

The main goal of this study is to evaluate how safe nivolumab is when used by itself or with other cancer treatments over a long period. This study includes patients with various types of tumors who have been part of a previous study and are continuing their treatment.

Eligibility Criteria

Inclusion Criteria

  • Must have signed a written informed consent form.
  • Eligible to continue receiving treatment as per the previous study, including continuing treatment even if the cancer has progressed, as determined by the doctor in the previous study.
  • Currently on a treatment break in the previous study after a long-lasting response or eligible to restart treatment as defined in the previous study.
  • Women of childbearing potential and sexually active male participants must agree to use effective contraception methods as described in the consent form.

Exclusion Criteria

  • Not eligible for treatment according to the previous study's criteria.
  • Not experiencing any clinical benefit from the treatment as assessed by the doctor.
  • Any health issue, lab result, or illness that, in the doctor's opinion, makes participation in the study not in the participant's best interest.
  • Other specific inclusion and exclusion criteria as defined in the study protocol.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.